| This week's sponsor is Premier Research. | | | Overcoming Risk in Oncology Drug Development
Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Click here for tips on finding the fast track. Premier Research. Built for biotech. |
Today's Rundown Bain creates $1.1B fund for fresh round of life science bets GSK teams up with Doudna, putting CRISPR to work to find new drugs Gilead, AbCellera ink infectious disease antibody discovery pact [Sponsored] Advancing a Diabetes Multi-Registration Program BlackThorn bags $76M to push targeted treatments for brain disorders Dassault Systemes eyes life science boost with $5.7B Medidata buy A CRISPR alternative for editing genes without cutting Featured Story | | | Thursday, June 13, 2019 Bain Capital has raised a $1.1 billion life sciences fund to place another round of big bets. The fund sets Bain up to continue striking eye-catching deals such as the Pfizer spinouts it bankrolled through its first life science investment vehicle. |
|
|
Top Stories Thursday, June 13, 2019 GlaxoSmithKline is joining forces with the University of California to dig into how gene mutations cause disease and to use CRISPR to discover new drugs. The partners will set up a laboratory that will net up to $67 million in funding over five years. Thursday, June 13, 2019 Gilead Sciences has entered into an infectious disease antibody discovery pact with AbCellera. The deal sees Gilead task AbCellera with using technologies to find rare antibodies with certain characteristics. Monday, June 10, 2019 Read the case study to learn how Covance helped a sponsor who wanted to get all sites for a 2,700 patient study up and running as quickly as possible. Covance leveraged their proprietary historical investigator performance database to see which investigators outperformed their peers on a consistent basis and had the capacity to run multiple studies at the same time. Thursday, June 13, 2019 BlackThorn Therapeutics raised $76 million to push targeted treatments for mood disorders into phase 2 studies and keep working on the machine learning-based technology that underlies its clinical pipeline. Thursday, June 13, 2019 Clinical trial specialist Medidata is being bought out by France’s Dassault Systemes in a deal designed to help the tech firm diversify deeper into the biopharma services world. Thursday, June 13, 2019 CRISPR-Cas9 gene editing requires cutting DNA, which can lead to errors. Scientists at Columbia University are proposing an alternative that uses a transposon to precisely insert DNA sequences in any site on the genome. | This week's sponsor is Cobra Biologics. | | |
Cobra provides expert scale up and manufacturing of customers’ live biotherapeutic microbiota products, manufacturing to cGMP standards for clinical and commercial scale. We also offer DNA and viral vector services, with experienced project teams nurturing customers’ products within GMP approved facilities. Visit our website to find out more. |
Resources Sponsored by: OCT Clinical Trials | June 20, 2019 | 2pm EDT / 11am PDT Fast and cost-efficient patient-enrollment,100% success strategy for obtaining a CTA, unified market authorization across the EEU countries. Find out the key compelling reasons to conduct studies in Russia. Sponsored by: AlphaSense What is agile competitive intelligence, and how can it help take market research to the next level? Sponsored by: Reprints Desk, Inc. Get 5 quick tips for faster research and better results! Sponsored by: Blue Latitude Health In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report. Sponsored by: Patheon, by Thermo Fisher Scientific Increase Safety & Flexibility with Flow Chemistry Sponsored by: Veeva IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now. Sponsored by: WCG Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: JPEO-CBRND – Medical Countermeasure Systems MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter. Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 